GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
Scientists have discovered that the shingles vaccine Shingrix, developed by GSK Plc (NYSE:GSK), may reduce the risk of dementia, a finding that could significantly impact public health.
科學家們發現，由GlaxoSmithKline（紐交所：GSK）開發的帶狀皰疹疫苗Shingrix可能會降低癡呆風險，這一發現可能會對公共健康產生重大影響。
The research, published in Nature Medicine, showed that individuals vaccinated with Shingrix lived an average of 164 days longer without a dementia diagnosis compared to those who received the older Zostavax vaccine.
《自然醫學》發表的研究表明，接種Shingrix疫苗的個體被診斷爲癡呆的時間比接種老版本的Zostavax疫苗的個體多長164天。
Related: GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
相關：GSK表示其暢銷帶狀皰疹疫苗在10年後仍表現出高效性
The study, led by Maxime Taquet, a clinical lecturer in Oxford University's psychiatry department, analyzed data from 200,000 people.
牛津大學精神病學系的臨床講師Maxime Taquet帶領的研究分析了20萬人的數據。
Taquet stated the findings were "convincing" and called for further research to validate the hypothesis that shingles vaccination might prevent dementia.
Taquet稱發現令人信服，並呼籲進一步研究驗證帶狀皰疹疫苗可能預防癡呆症的假設。
Shingles is an infection caused by a virus. The main symptom is a painful rash. The virus that causes shingles is called varicella zoster.
帶狀皰疹是由病毒引起的感染。主要症狀是疼痛性皮疹。引起帶狀皰疹的病毒稱爲水痘-帶狀皰疹病毒。
Shingles, or herpes zoster, occurs when the dormant varicella-zoster virus, which causes childhood chickenpox, reactivates.
帶狀皰疹或稱爲Herpes zoster，是指引起兒童水痘的休眠水痘-帶狀皰疹病毒重新激活的疾病。
The switch from Zostavax to Shingrix in the U.S. health systems in 2017 allowed researchers to compare dementia rates among over 100,000 individuals vaccinated with either vaccine.
2017年在美國健康系統中從Zostavax轉換到Shingrix疫苗，使研究人員能夠比較接種其中一種疫苗的超過100,000人的癡呆率。
Shingrix showed a 17% lower risk of dementia than Zostavax and a 23-27% lower risk than vaccines for other infections, such as flu and tetanus.
Shingrix疫苗的癡呆風險比Zostavax低17％，比其他感染（如流感和破傷風）的疫苗風險低23-27％。
Citing Sheona Scales, director of research at the Alzheimer's Research U.K. charity, the Financial Times report stressed the importance of further research to understand the biological mechanisms behind Shingrix's potential protective effect against dementia.
引用阿爾茨海默病研究英國慈善機構的研究主管Sheona Scales的話，金融時報報道強調了進一步研究理解Shingrix潛在保護作用背後的生物機制的重要性。
While the study adds to the evidence linking shingles vaccination with reduced dementia risk, Scales also pointed out other established dementia risk factors.
儘管該研究增加了接種帶狀皰疹疫苗與降低癡呆風險之間的證據，但Scales指出了其他已知的癡呆風險因素。
Shingrix has become one of GSK's top-selling products, generating 3.4 billion pounds in revenue worldwide in 2023, with Q4 2023 representing the highest-ever quarter of sales.
Shingrix已成爲GSK最暢銷的產品之一，在2023年全球實現34億英鎊的營業收入，Q4 2023年實現了有史以來最高的季度銷售額。
GSK acknowledged the new study as part of the "growing body of evidence" suggesting a connection between shingles vaccination and reduced dementia risk.
GSK將這項新研究視爲表明帶狀皰疹疫苗與降低癡呆風險之間存在聯繫的“越來越多的證據”之一。
The company plans to present additional data on Shingrix at an upcoming Alzheimer's conference in Philadelphia.
該公司計劃在即將於費城舉行的阿爾茨海默病會議上展示有關Shingrix的補充數據。
Price Action: GSK stock is up 2.50% at $40.04 at the last check on Friday.
股價表現：上週五最後一次查詢時，GSK股價上漲2.50％，報40.04美元。
- Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast.
- Bristol Myers Squibb區分“新藥”需求旺盛，2022年第二季度盈利超過預期，將2024年盈利預期上調。
Photo via Wikimedia Commons
照片通過Wikimedia Commons
譯文內容由第三人軟體翻譯。